

CLAIM AMENDMENTS

1. (original) An isolated SARS-related protein having a molecular weight of approximately 47 kDa.

2. (original) The protein of claim 1, having a sequence as shown in Figure 1 and homologs, analogs, fragments or derivatives thereof.

3. (original) An isolated SARS-related protein having a molecular weight of approximately 139 kDa.

4. (original) The protein of claim 3, having a sequence as shown in Figure 2 and homologs, analogs, fragments or derivatives thereof.

5. (amended) An antibody reactive against a protein according to ~~any one of claims 1 to 4~~.

6. (original) A method of detecting a coronavirus or a condition associated with a coronavirus comprising assaying a sample for (a) a SARS-related protein or a fragment thereof; or (b) an antibody that binds a SARS-related protein or a fragment thereof.

7. (amended) A method according to claim 6 which comprises contacting a SARS-related protein of ~~any one of claims 1 to 4~~ or a functional fragment thereof, with the sample and determining the presence of antibodies to the SARS-related protein in the sample.

8. (original) A method according to claim 6 which comprises contacting an antibody of claim 5, or a functional fragment thereof, with the sample and determining the presence of a SARS-related protein in the sample.

9. (amended) A method according to ~~any one of claims 6 to 8~~ wherein the condition is SARS.

10. (original) A method of treating or preventing a condition associated with coronavirus comprising administering an effective amount of a SARS-related protein antagonist.

11. (original) A method according to claim 10 wherein said SARS-related protein antagonist is an antibody according to claim 5.

12. (amended) A method according to claim 10 ~~or 14~~ wherein said condition is SARS.

13. (original) A vaccine for treating or preventing a condition associated with a coronavirus comprising an effective amount of (a) a SARS-related protein or fragment thereof; or (b) an antibody that binds a SARS-related protein in admixture with a suitable diluent or carrier.


14. (amended) A method of screening for a compound capable of binding to a protein according to ~~any one of~~ claims 1 ~~to~~ 4, or a functional fragment thereof comprising contacting the polypeptide or functional fragment thereof with a test compound and determining the ability of said test compound to bind to said protein or fragment thereof.

15. (original) A compound identified according the method of claim 14.

16. (original) The compound of claim 14 wherein said compound is an agonist or antagonist.

Respectfully submitted

Steven Jones et al.

PER:   
\_\_\_\_\_  
Michael Williams  
Registration 45,333

October 13, 2005

Winnipeg, Manitoba, Canada  
Telephone (204) 947- - FAX (204) 942-5723